We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The generic manufacturers are accused of “routinely and systematically” communicating with each other to determine their market share and customers. Read More
A new draft guidance from the FDA encourages drugmakers to speed up development of Hepatitis D treatments for use in the U.S., offering recommendations for innovative trial designs, target populations and endpoints. Read More
Acting FDA Commissioner Ned Sharpless ends his six-month stint at the agency today, and the White House is expected to nominate oncologist Stephen Hahn to fill the permanent role. Read More
Clinical trial results showed that the treatment induced and maintained clinical remission in a significantly higher proportion of adult patients compared to a placebo. Read More